grant
MRNA VACCINE DEVELOPMENT
Organization FLAG BIO, INC.Location EAST AURORA, UNITED STATESPosted 1 Sept 2024Deadline 31 Aug 2026
NIHUS FederalResearch GrantFY20242019-nCoV vaccineAgonistCOVID-19 vaccineCaliforniaContractorDependenceDoseFormulationGrippeH1N1H1N1 VirusHemagglutininImmune responseImmunological responseIn VitroInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza HAInfluenza HemagglutininMessenger RNAMiceMice MammalsMurineMusPharmacodynamicsRNA vaccineRNA-based vaccineSARS-CoV-2 vaccineSARS-coronavirus-2 vaccineSeriesSevere Acute Respiratory Syndrome CoV 2 vaccineSevere acute respiratory syndrome coronavirus 2 vaccineSpecificityTIL3TLR5TLR5 geneTLR5 receptorToll-Like Receptor 5Toll/Interleukin-1 Receptor-Like Protein 3ToxicologyTranscriptVaccinatedVaccine AdjuvantVaccinesVariantVariationanti-fluanti-influenzaantiflucell transductioncellular transductioncoronavirus disease 2019 vaccinecoronavirus disease-19 vaccinede-immunizationde-immunizedeimmunizationdeimmunizedesigndesigningdetermine efficacydevelop a vaccinedevelop vaccinesdevelopment of a vaccineefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyflu HAflu hemagglutininflu infectionflu virus infectionhost responseimmune system responseimmunoresponseinfected with fluinfected with flu virusinfected with influenzainfected with influenza virusinfluenza infectioninfluenza viral HAinfluenza viral hemagglutinininfluenza virus HAinfluenza virus hemagglutinininfluenza virus infectionmRNAmRNA lipid nano particle vaccinemRNA vaccinemRNA-LNP based vaccinemRNA-LNP combination vaccinesmRNA-LNP vaccinesmRNA-based vaccinemouse modelmurine modelnCoV vaccinenCoV-19 vaccinenCoV19 vaccinepolypeptidepre-clinical efficacypreclinical efficacytoll-5 receptortransduced cellsvaccine against 2019-nCovvaccine against COVID-19vaccine against SARS-CoV-2vaccine against SARS-coronavirus-2vaccine against Severe Acute Respiratory Syndrome CoV 2vaccine against Severe acute respiratory syndrome coronavirus 2vaccine candidates against SARS-CoV-2vaccine developmentvaccine for novel coronavirusvaccines preventing COVIDvaccines to prevent COVID
Full Description
The contractor will develop mRNAFlag as a vaccine adjuvant. mRNAFlag is an mRNA transcript that encodes for the deimmunized TLR5 agonist GP532. mRNAFlag would be developed within the context of an influenza mRNA vaccine, using an A/California/07/2009(H1N1) hemagglutinin in an LNP formulation used by Moderna for its SARS-CoV-2 vaccine.
Grant Number: 75N93024C00014-0-9999-1
NIH Institute/Center: NIH
Principal Investigator: KATERINA ANDRIANOVA
Sign up free to get the apply link, save to pipeline, and set email alerts.
Sign up free →Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click